Ramachandran Raja, Kumar Vivek, Rathi Manish, Nada Ritambhra, Jha Vivekanand, Gupta Krishan Lal, Sakhuja Vinay, Kohli Harbir Singh
Department of Nephrology, PGIMER, Chandigarh, India.
Department of Histopathology, PGIMER, Chandigarh, India.
Nephrol Dial Transplant. 2014 Oct;29(10):1918-24. doi: 10.1093/ndt/gfu097. Epub 2014 Apr 24.
Management of adults with steroid-resistant (SR) nephrotic syndrome due to focal segmental glomerulosclerosis (FSGS) is a challenging task. Is tacrolimus (TAC) effective in this situation without serious adverse effects? This prospective study was done to answer this question.
In patients with SR nephrotic syndrome due to FSGS, oral TAC (0.1 mg/kg/day) was started targeting a trough level of 5-10 ng/mL along with oral prednisolone (0.15 mg/kg/day) for 48 weeks. In patients with complete remission (CR), TAC dose was reduced to a target of 3-6 ng/mL whereas in partial responders, TAC trough levels were kept at 5-10 ng/mL. TAC was discontinued in those with no remission at 24 weeks and was deemed TAC resistant. Outcome, namely CR and partial remission (PR), was assessed at the end of 24 and 48 weeks. All patients were prospectively followed for 60 weeks. Relapses after CR or PR were recorded; adverse effects, namely nephrotoxicity (>25% rise in creatinine), cosmetic effects, infections and hyperglycemia, were recorded every month.
A total of 44 SR-FSGS [not otherwise specified 33 (75%), tip lesion 03 (6.8%) and cellular variant 8 (18.1%)] were analyzed. Mean age was 25.16 ± 8.26 (18-51) years. Of 44 patients, CR and PR were achieved in 17 (38.6%) and 06 (13.6%) patients, respectively. TAC resistance was seen in 21 (47.7%) patients. Time taken to achieve remission was 15.2 ± 6 weeks. Five (21.7%) patients with CR had relapse on tapering the dose and seven (30.4%) after stopping TAC. Reversible nephrotoxicity was seen in seven (15.9%) and irreversible in four patients (9%). TAC-related diarrhea was the problem in 10 (22.7%), and infections were seen in 19 patients (43.1%). Impaired fasting glucose and diabetes mellitus were seen in 10 patients (22.7%).
TAC is an effective agent in the management of SR-FSGS. However, strict renal function and blood sugar monitoring is required due to its potential nephrotoxicity and diabetogenic potential.
局灶节段性肾小球硬化(FSGS)所致成人激素抵抗(SR)性肾病综合征的管理是一项具有挑战性的任务。他克莫司(TAC)在这种情况下是否有效且无严重不良反应?本前瞻性研究旨在回答这一问题。
对于FSGS所致SR肾病综合征患者,开始口服TAC(0.1mg/kg/天),目标谷浓度为5 - 10ng/mL,同时口服泼尼松龙(0.15mg/kg/天),持续48周。完全缓解(CR)的患者,TAC剂量减至目标值3 - 6ng/mL;部分缓解者,TAC谷浓度维持在5 - 10ng/mL。24周时未缓解的患者停用TAC,视为TAC抵抗。在24周和48周结束时评估结局,即CR和部分缓解(PR)。所有患者前瞻性随访60周。记录CR或PR后的复发情况;每月记录不良反应,即肾毒性(肌酐升高>25%)、外观影响、感染和高血糖。
共分析了44例SR - FSGS患者[未另作说明者33例(75%),顶端病变3例(6.8%),细胞型8例(18.